Live Breaking News & Updates on Low Clinical Activity Score|Page 1

Stay updated with breaking news from Low clinical activity score. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Horizon Therapeutics plc Reports Second-Quarter 2023 Financial Results

Second-Quarter 2023 Results:
Net Sales of $945.0 Million, Representing Year-Over-Year Growth of 11% Excluding Inflammation Medicines
GAAP Net Income of $127.1 Million; Adjusted EBITDA of. ....

United States , Tim Walbert , European Congress , Amgen Inc , Apotex Inc , United States Federal Trade Commission , Companies To Work , Viela Bio Inc , Top Biotechnology Pharmaceutical Company , Representing Year Over Growth , Excluding Inflammation , Net Sales , Recent Company Highlights , Positive Topline Data , Low Clinical Activity Score , Thyroid Eye Disease , Specify Treatment , Disease Activity , First Country Outside , Daxdilimab Phase , New Data , Dazodalibep Phase , Controlled Trial , Expect Amgen Transaction , Federal Trade Commission , Work For ,

Horizon Therapeutics plc Reports First-Quarter 2023 Financial Results

First-Quarter 2023 Results:
Net Sales of $832.1 Million
GAAP Net Income of $54.7 Million; Adjusted EBITDA of $232.9 Million
TEPEZZA® Net Sales of $405.3 Million
. | May 3, 2023 ....

United States , Tim Walbert , Viela Bio Inc , Companies To Work , Top Biotechnology Pharmaceutical Company , Clinical Program Expected To , Amgen Inc , Apotex Inc , United States Federal Trade Commission , Net Sales , Recent Company Highlights , Positive Topline Data , Low Clinical Activity Score , Thyroid Eye Disease , Specify Treatment , Disease Activity , Second Population , Syndrome Phase , Only Phase , Syndrome Trial , Primary Endpoint , Both Patient Populations , Program Expected , Two Daxdilimab Phase , Discoid Lupus Erythematosus , Expect Amgen Transaction ,

Horizon Therapeutics plc Reports Fourth-Quarter and Full-Year 2022 Financial Results

Fourth-Quarter 2022 Results: Net Sales of $942.0 Million GAAP Net Income of $120.4 Million; Adjusted EBITDA of $357.5 Million; Includes $37.3 Million of Acquired IPR&D and Milestones Expenses ....

United States , Dennis Riedl , Geoff Curtis , Tim Walbert , Tina Ventura , Ray Gordon , Erin Linnihan , Clinical Program Expected To , Alkem Laboratories Inc , Amgen Inc , Corporate Affairs , Apotex Inc , Net Sales , Year Over Increase , Record Adjusted , Operating Cash Flow , Recent Company Highlights , Transaction Expected , Positive Topline Data , Second Population , Syndrome Phase , Only Phase , Syndrome Trial , Primary Endpoint , Both Patient Populations , Program Expected ,

Horizon Therapeutics plc Reports Third-Quarter 2022 Financial Results; Increases Full-Year 2022 Net Sales and Adjusted EBITDA Guidance; Increases TEPEZZA and KRYSTEXXA Peak Annual Net Sales Expectations

Third-Quarter 2022 Results: Net Sales of $925.4 Million GAAP Net Income of $135.8 Million; Adjusted EBITDA of $335.3 Million, Which Includes $19.0 Million of Acquired IPR&D and Milestones ....

United States , Geoff Curtis , Tim Walbert , Tina Ventura , Ray Gordon , Erin Linnihan , Companies That Care , Share Repurchase Program , Subcutaneous Sc Administration Trial , American College Of Rheumatology , Key Clinical Development Programs , Development For The Treatment Of Autoimmune Diseases , Research In Multiple Sclerosis , Clinical Program , Apotex Inc , Division Of Corporation , Company Board Of Directors , Drug Administration , American Academy Of Ophthalmology , American Thyroid Association , Alkem Laboratories Inc , Exchange Commission , European Alliance Of Associations , Brazil National Health Surveillance Agency , Seramount Best Companies For Dad , European Committee For Treatment ,

Horizon Therapeutics plc Reports Second-Quarter 2022 Financial Results and Revises Full-Year 2022 Ne

Second-Quarter 2022 Results: Net Sales of $876.4 Million; Orphan Segment Net Sales Increased 13% to $841.3 Million GAAP Net Income of $61.0 Million; Adjusted EBITDA of $306.6 Million TEPEZZA® (teprotumumab-trbw) Net Sales of $479.8 Million KRYSTEXXA® (pegloticase injection) Net Sales of $167.8 Milli. ....

United States , Ruth Venning , Tim Walbert , Tina Ventura , Geoff Curtis , Erin Linnihan , Subcutaneous Sc Administration Trial , Alkem Laboratories Inc , Communications Officer , Corporate Affairs , Apotex Inc , Orphan Segment Net Sales Increased , Net Sales , Sales Guidance , Reflecting Revised Net Sales Expectations , Sales Percentage Growth , Company Highlights , Include Co Administration , Methotrexate Based , That Demonstrated Improved , Sustained Patient , European Commission , Adult Patients , Commercial Launch Underway , Horizon Therapeutics , Recent Company ,